Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDIGO golimumab dose-interval pharmacokinetic comparison
2019-004101-27Phase 4Active
- Sponsor
- Sint Maartenskliniek
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), sponsored by Sint Maartenskliniek. Primary endpoints: Peak golimumab serum levels, Trough golimumab serum levels and 1 more. Started Dec 2019; status: active.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2019-004101-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004101-27.